- Previous Close
3.070 - Open
3.000 - Bid 3.000 x --
- Ask 3.020 x --
- Day's Range
3.000 - 3.010 - 52 Week Range
2.350 - 34.300 - Volume
59,400 - Avg. Volume
217,708 - Market Cap (intraday)
313.029M - Beta (5Y Monthly) -0.27
- PE Ratio (TTM)
-- - EPS (TTM)
-8.330 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
72.14
Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops product candidates for indications with medical needs. The company's therapeutics products focus on oncology and fibrosis, anticoagulant therapies, cardiometabolic disease, complement-mediated diseases, medical aesthetics, and viral infections. Its lead drug candidates include STP705 for the treatment of non-melanoma skin cancer and for focal fat reduction; and STP707 to treat solid tumors. The company is also developing STP355 for the treatment of multiple solid tumors, including breast cancer, melanoma, and colorectal cancer; STP369 to treat head and neck and bladder cancer; STP705 for focal fat reduction; STP122G to treat coagulation disorders; STP125G to treat hypertriglyceridemia; and STP144G for the treatment of complement diseases. In addition, it is developing RV-1730, a Covid-19 vaccine; RV-1770, a respiratory syncytial virus vaccine; STP247G, STP144G, STP145G, and STP146G for the treatment of complement diseases; STP152G for ATTR amyloidosis indication; STP136G to treat hypertension; STP251G for treating hemochromatosis and hypertriglyceridemia; and STP237G to treat hypertension and hypertriglyceridemia. The company was founded in 2007 and is based in Wan Chai, Hong Kong.
www.sirnaomics.comRecent News: 2257.HK
View MorePerformance Overview: 2257.HK
Trailing total returns as of 1/16/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2257.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2257.HK
View MoreValuation Measures
Market Cap
320.33M
Enterprise Value
312.27M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
168.61
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.84%
Return on Equity (ttm)
-342.57%
Revenue (ttm)
1.08M
Net Income Avi to Common (ttm)
-81.8M
Diluted EPS (ttm)
-8.330
Balance Sheet and Cash Flow
Total Cash (mrq)
9.67M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
6.07M